Erythromycin, Retapamulin, Pyridoxine, Folic acid, and Ivermectin dose-dependently inhibit cytopathic effect, Papain-like Protease, and MPRO of SARS-CoV-2
Bello, S. O.; Imam, M. U.; Bello, M. B.; Yunusa, A.; Adamu, A. A.; Shuaibu, A.; Igumbor, E. U.; Habib, Z. G.; Popoola, M. A.; Ochu, C. L.; Bello, A. Y.; Deeni, Y. Y.; Okoye, I.
Show abstract
We previously showed that Erythromycin, Retapamulin, Pyridoxine, Folic acid and Ivermectin inhibit SARS-COV-2 induced cytopathic effect (CPE) in Vero cells. In this study and using validated quantitative neutral red assay, we show that the inhibition of CPE is concentration dependent with Inhibitory Concentration-50(IC50) of 3.27 M, 4.23 M, 9.29 M, 3.19 M and 84.31 M respectively. Furthermore, Erythromycin, Retapamulin, Pyridoxine, Folic acid and Ivermectin dose dependently inhibit SARS-CoV-2 Papain-like Protease with IC50 of 0.94 M, 0.88 M, 1.14 M, 1.07 M, 1.51 M respectively and the main protease(MPRO) with IC50 of 1.35 M, 1.25 M, 7.36 M, 1.15 M and 2.44 M respectively. The IC50 for all the drugs, except ivermectin, are at the clinically achievable plasma concentration in human, which supports a possible role for the drugs in the management of COVID-19. The lack of inhibition of CPE by Ivermectin at clinical concentrations could be part of the explanation for its lack of effectiveness in clinical trials.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 97%
- Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro 96%
- Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial 94%
Similar papers in this journal
- Metal Coordinating Inhibitors of Rift Valley Fever virus Replication 95%
- High-throughput phenotypic screen identifies a new family of potent anti-amoebic compounds 94%
- Exploring the cytotoxic mechanisms of Pediocin PA-1 towards HeLa and HT29 cells by comparison to known bacteriocins: Microcin E492, Enterocin Heterodimer and Divercin V41. 94%
Similar papers in this journal
- Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles 94%
- Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay 93%
- Target-driven design of a coumarinyl chalcone scaffold based novel EF2 Kinase inhibitor suppresses breast cancer growth in vivo 92%
Similar papers in this journal
- Methylene Blue has a potent antiviral activity against SARS-CoV-2 in the absence of UV-activation in vitro 95%
- Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors 94%
- The Effect Of Famotidine On SARS-CoV-2 Proteases And Virus Replication 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.